Zacks Investment Research upgraded shares of Kura Oncology (NASDAQ:KURA) from a sell rating to a buy rating in a research note issued to investors on Tuesday. Zacks Investment Research currently has $18.00 price objective on the stock.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
Other research analysts also recently issued research reports about the stock. BidaskClub raised shares of Kura Oncology from a hold rating to a buy rating in a research report on Thursday, July 12th. HC Wainwright set a $31.00 price target on shares of Kura Oncology and gave the company a buy rating in a research note on Tuesday, August 7th. Finally, Oppenheimer increased their price target on shares of Kura Oncology from $27.00 to $35.00 and gave the company an outperform rating in a research note on Monday, July 9th. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $26.33.
Kura Oncology stock opened at $15.89 on Tuesday. The firm has a market capitalization of $664.57 million, a P/E ratio of -10.45 and a beta of 4.20. Kura Oncology has a 1-year low of $12.10 and a 1-year high of $24.02. The company has a quick ratio of 10.22, a current ratio of 10.22 and a debt-to-equity ratio of 0.04.
Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, August 9th. The company reported ($0.45) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.45). On average, research analysts anticipate that Kura Oncology will post -1.73 earnings per share for the current year.
A number of hedge funds have recently made changes to their positions in KURA. Victory Capital Management Inc. acquired a new stake in Kura Oncology in the second quarter valued at $27,104,000. Eagle Asset Management Inc. acquired a new stake in Kura Oncology in the second quarter valued at $24,881,000. Carillon Tower Advisers Inc. acquired a new stake in Kura Oncology in the second quarter valued at $16,853,000. BlackRock Inc. lifted its stake in Kura Oncology by 25.5% in the second quarter. BlackRock Inc. now owns 2,002,265 shares of the company’s stock valued at $36,440,000 after acquiring an additional 406,963 shares during the last quarter. Finally, Prosight Management LP acquired a new stake in Kura Oncology in the second quarter valued at $5,240,000. Hedge funds and other institutional investors own 77.28% of the company’s stock.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Further Reading: Outstanding Shares
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.